Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial preferentially use the VH1 gene family ; volume:9 ; number:2 ; day:13 ; month:9 ; year:2012 ; pages:1 ; date:9.2012
Retrovirology ; 9, Heft 2 (13.9.2012), 1, 9.2012
- Creator
-
Bonsignori, M.
- Contributor
-
Pollara, J.
Moody, MA
Kepler, TB
Chen, X.
Gurley, TC
Kozink, DM
Marshall, DJ
Whitesides, JF
Kaewkungwal, J.
Nitayaphan, S.
Pitisuttithum, P.
Rerks-Ngarm, S.
Kim, JH
Michael, NL
Montefiori, DC
Liao, H.
Ferrari, G.
Haynes, BF
SpringerLink (Online service)
- DOI
-
10.1186/1742-4690-9-S2-P78
- URN
-
urn:nbn:de:1111-2016080727313
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bonsignori, M.
- Pollara, J.
- Moody, MA
- Kepler, TB
- Chen, X.
- Gurley, TC
- Kozink, DM
- Marshall, DJ
- Whitesides, JF
- Kaewkungwal, J.
- Nitayaphan, S.
- Pitisuttithum, P.
- Rerks-Ngarm, S.
- Kim, JH
- Michael, NL
- Montefiori, DC
- Liao, H.
- Ferrari, G.
- Haynes, BF
- SpringerLink (Online service)
Other Objects (12)
Critical role for monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity
Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies
Antibodies as carriers of cytotoxicity
The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer
Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
Improved antibody-dependent cell-mediated cytotoxicity (ADCC) of affinity maturated and Fc-engineered antibodies directed against the AML stem cell antigen CD96
Improved Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) of Affinity Maturated and Fc-Engineered Antibodies Directed Against the AML Stem Cell Antigen CD96
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition
Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity
Critical role for monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity
Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies
Antibodies as carriers of cytotoxicity
The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer
Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
Improved antibody-dependent cell-mediated cytotoxicity (ADCC) of affinity maturated and Fc-engineered antibodies directed against the AML stem cell antigen CD96
Improved Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) of Affinity Maturated and Fc-Engineered Antibodies Directed Against the AML Stem Cell Antigen CD96
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition
Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity
Critical role for monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity
Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies
Antibodies as carriers of cytotoxicity
The impact of CLDN18.2 expression on effector cells mediating antibody-dependent cellular cytotoxicity in gastric cancer
Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity
Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition
Improved antibody-dependent cell-mediated cytotoxicity (ADCC) of affinity maturated and Fc-engineered antibodies directed against the AML stem cell antigen CD96
Improved Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) of Affinity Maturated and Fc-Engineered Antibodies Directed Against the AML Stem Cell Antigen CD96
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Correction to: Immunotherapy Utilizing the Combination of Natural Killer– and Antibody Dependent Cellular Cytotoxicity (ADCC)–Mediating Agents with Poly (ADP-ribose) polymerase (PARP) Inhibition